Market Overview on Relapsing Remitting Multiple Sclerosis - Pipeline Review, H2 2016

Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) pipeline landscape.

Relapsing-remitting multiple sclerosis (RRMS) is the most common form of multiple sclerosis (MS). In RRMS, there are clear episodes of inflammatory activity (relapses). During a period of acute inflammation, old symptoms may worsen and new symptoms may appear. A relapse is when active inflammation, and the resulting symptoms, last more than 24 hours. Symptoms include tingling or numbness, double vision, fatigue, urinary urgency and weakness. Treatment includes corticosteroids and immunoglobulin therapy.

Complete report available @ Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2016

Report Highlights

This report provides comprehensive information on the therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 18, 1, 6 and 1 respectively for Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively for Relapsing Remitting Multiple Sclerosis (RRMS).

Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

AB Science SA AbbVie Inc Actelion Ltd Alkermes Plc Amarna Therapeutics B.V. Antisense Therapeutics Limited Biocon Limited Biogen Inc Cognosci, Inc. Coherus BioSciences, Inc. Forward Pharma A/S GeNeuro SA GlaxoSmithKline Plc Iltoo Pharma LFB S.A. Mapi Pharma Ltd. MedImmune, LLC Merck KGaA Mitsubishi Tanabe Pharma Corporation Neurotec Pharma SL Novartis AG Octapharma AG Opexa Therapeutics, Inc. RedHill Biopharma Ltd. Teva Pharmaceutical Industries Ltd. Xenetic Biosciences (UK) Limited Zydus Cadila Healthcare Limited

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###